CONCISE REVIEW IN MECHANISMS OF DISEASE

Albumin: Biochemical Properties and Therapeutic Potential

Gregory J. Quinlan,1 Greg S. Martin,2 and Timothy W. Evans1 uman serum albumin (HSA) is an abundant multifunctional non-glycosylated, negatively charged plasma protein, with ascribed ligand-binding and transport properties, antioxidant functions, and enzymatic activities.1 It is synthesized primarily in the liver and is thought to be a negative acute-phase protein. Physiologically, albumin is responsible for maintaining colloid osmotic pressure and may inuence microvascular integrity and aspects of the inammatory pathway, including neutrophil adhesion and the activity of cell signaling moieties. Clinically, albumin has been employed as a plasma expander in many patient populations, although the evidence from meta analyses2,3 and the recently published SAFE investigation4 suggests it does not afford a survival benet over crystalloid solutions when administered to the critically ill. However, studies of albumin usage as a volume expander and albumin dialysis therapy in patients with liver disease have led to some encouraging results. This review aims to highlight current thinking regarding albumin therapy in the critical care and hepatological setting and also discusses other potential therapeutic applications for its use based around the complex biochemistry of this multifunctional plasma protein. Potential contraindications are also discussed.

Tertiary Structure and Biochemical Characteristics of Albumin

Albumin normally accounts for over 50% of total plasma protein content, being present at concentrations
Abbreviations: HSA, human serum albumin; NO, nitric oxide; ROS, reactive oxygen species; RNS, reactive nitrogen species; COP, colloid oncotic pressure. From the 1Department of Critical Care Medicine, Imperial College School of Medicine, Royal Brompton Hospital, London, UK; and the 2Department of Pulmonary and Critical Care Medicine, Emory University School of Medicine, Atlanta, GA. Received September 21, 2004; accepted March 21, 2005. Address reprint requests to: Professor TW Evans, Royal Brompton Hospital, Sydney Street, London SW3 6NP, United Kingdom. E-mail: t.evans@ rbh.nthames.nhs.uk; fax: (44) 207 351 8524. Copyright 2005 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hep.20720 Potential conict of interest: G.J.Q., G.S.M., and T.W.E. have received nondirected grants from agencies representing albumin manufacturers (Plasma Protein Therapuetics Association).

of approximately 0.6 mmol/L. HSA is a small (66 kd) globular protein composed of 585 amino acids, with few tryptophan or methionine residues but an abundance of charged residues such as lysine, and aspartic acids and no prosthetic groups or carbohydrate. X-ray crystallography has shown albumin to possess a heart-shaped tertiary structure, but in solution HSA is ellipsoid. Some 67% of the tertiary structure of HSA is composed of -helices. Indeed, the protein is composed of 3 homologous domains (I-III), each containing two sub-domains (A and B) composed of 4 and 6 -helices respectively. The subdomains move relative to one another by means of exible loops provided by proline residues, which helps accommodate the binding of an array of substances, as does the exibility provided by domain-linking disulde bridges. Figure 1 depicts the tertiary structure with bound fatty acids. HSA contains 35 cysteine residues, most of which form disulde bridges (17 in all), contributing to overall tertiary structure. However, it also contains 1 free cysteine-derived, redox active, thiol (-SH) group (Cys-34), which accounts for 80% (500 mol/L) thiols in plasma . The thiol moiety of Cys-34 is reactive and capable of thiolation (HSA-S-R) and nitrosylation (HSA-S-NO), processes that are thought to contribute to several in vivo functions. Physiologically, HSA exists predominantly in a reduced form (that is, with a free thiol, HSA-SH) and is known as mercaptoalbumin. However, a small but significant proportion of the albumin pool exists as mixed disuldes (HSA-S-S-R); where (R) represents lowmolecular-weight, thiol-containing substances in plasma, chiey cysteine and glutathione. Mixed disulde formation also increases as part of the aging process (reviewed by Droge5) and during disease processes characterized by oxidative stress. Dimer formation is also theoretically possible (HSA-S-S-ASH), but in practice is unlikely to occur in vivo because of stearic interference. However, this process is known to occur ex vivo on purication and storage and therefore may have implications related to certain aspects of the therapeutic use of albumin.

Properties of Albumin
Ligand-Binding. HSA binds many endogenous and exogenous compounds, including fatty acids, metal ions, pharmaceuticals, and metabolites, with implications for drug delivery and efcacy, detoxication, and antioxidant protection. Several low- and high-afnity ligand-binding sites have been identied on HSA, the rst of which to be identied (termed site I and II) are responsible for the binding of most pharmaceuticals that interact with the protein. Sites I and II are located in different domains and
1211

1212

QUINLAN, MARTIN, AND EVANS

HEPATOLOGY, June 2005

Fig. 1. Tertiary structure of albumin showing the binding of seven archidonic acid ligands is depicted. Illustration obtained from the RCSB protein data bank PDB ID:1gnj by David S Goodsell Scripps Research Institute. Primary reference source: Petitpas I, Gruene T, Bhattacharya AA, Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 2001;314:955.

exhibit differential, but not always exclusive, ligand-binding afnities. Site I tends to bind relatively large heterocyclic compounds or dicarboxylic acids. A diverse array of unrelated compounds bind with high afnity to various locations within this site, indicating adaptability. Moreover, this site is large and able to bind bulky endogenous substances, including bilirubin and porphyrins. By contrast, site II (also known as the indole-benzodiazepine site) is smaller and less exible in nature, because binding is more stereo-specic. Importantly, additional high-afnity binding areas are present within HSA for some drugs and compounds that do not conform to either site I or II. Furthermore, the binding domains of some substances such as digitoxin and the bile acids remains to be elucidated; for a concise review on ligand-binding, see Kragh-Hansen et al.6 Cysteine-34 binds drugs including cisplatin, D-penicillamine, and N-acetyl-cysteine.6 Covalent interactions (thiolations) also occur with endogenous, low-molecularweight, thiol-containing substances via disulphide bridge formation. Higher oxidation states of cys-34 can also occur, resulting in the formation of sulfenic, sulnic, or sulfonic acid residues (Fig. 2), although levels seen in normal plasma (bovine) are low.7 Both endogenous and exogenous nitric oxide (NO) are known to interact with cys-34 via electrophilic addition of the nitrosonium ion

(NO). Indeed, until recently NO was thought to circulate in plasma primarily as an S-nitroso HSA adduct and to possess vasodilatory properties , augmented by NO transfer to low-molecular-weight thiols.8 However, recent in vitro and in vivo studies indicate that levels of s-nitrosoalbumin that form under biologically relevant conditions in normal plasma are in the low nanomolar range (10 nmol/L) and that several other reaction products of NO contribute to the NO plasma sink.9 It is less clear to what extent HSA contributes to NO binding in vivo under pathological conditions, or to what extent the availability of catalysts and or other NO-derived species impacts on s-nitrosolation. Furthermore, recent studies using a targeted s-nitrosoglutathione reductase murine model have demonstrated the importance of nitroso-thiol turnover in endotoxic shock.10 Further studies are required to determine HSAs role under such circumstances. Key reactions are summarized in Fig. 3. Metal Cations. The N-terminal portion of HSA (NAsp-Ala-His-Lys-) binds Cu, Ni, and Co ions with high afnity, whereas Au, Ag, and Hg ions bind to cysteine-34 (reviewed in Kragh-Hansen et al.6) HSA is also the major Zn binding protein in plasma, although there is some debate as to the nature of and location of its binding site.11 HSA has also been reported to possess a relatively weak, nonspecic, latent iron-binding capacity.12 This is, however, unlikely to be of signicance under normal circumstances in plasma, because the specic, high-afnity, ironbinding protein transferrin binds all low-molecular-mass ferric iron. Antioxidant Functions. Aerobic metabolism is energy efcient. However, whereas oxygen-containing end products of these processes are relatively innocuous, many

Fig. 2. Scheme gives an overview of the steps involved (highlighted in blue) for the nitrosylation of Cys-34 of human serum albumin (HSA). Nitric oxide (NO) requires an electron accepting catalyst (reactive transition metal ion, or metal-containing proteins) to favor such reactions. Steps leading to Cys-34 oxidation and thiolation are highlighted in red. Formation of higher oxidation states of HSA are also shown. RSH, glutathione or free cysteine; Alb, albumin.

HEPATOLOGY, Vol. 41, No. 6, 2005

QUINLAN, MARTIN, AND EVANS

1213

Fig. 3. Scheme depicts antioxidant (highlighted in blue) and the pro-oxidant potential (highlighted in red) of human serum albumin (HSA). The potential of iron and copper ions to catalyze the formation of the extremely aggressive and damaging hydroxyl radical OH (the Fenton reaction) is shown. The potential ability of HSA to redox cycle these metal catalysts exacerbates this pro-oxidant response when these metals have access to Cys-34, in other words, when they are not bound at protected sites on this protein or elsewhere. As shown, such metal salts also can propagate membrane lipid peroxidation directly if stable lipid peroxides are already present. Nitric oxide and bilirubin binding may provide an indirect (supportive) antioxidant response attributable to albumin, as both compounds have reported lipid-phase antioxidant function.

intermediates thereby formed are potentially, or directly, extremely reactive in nature. Such reactive oxygen species (ROS) can inict damage on molecules, leading to the accumulation of toxic end products and cellular dysfunction or damage. Normally, the body uses protective (i.e., antioxidant) and reparative systems that limit the effects of oxidative stress. An antioxidant is any substance that when present at low levels signicantly diminishes or prevents the oxidation of an oxidizable substrate, and may be dietary, constitutive, or inducible in origin. Primary antioxidants prevent ROS formation and include the ironbinding antioxidant transferrin. Secondary antioxidants scavenge pre-formed ROS. Examples include ascorbate and superoxide dismutase. For the denitive text on ROS in biology, see Gutteridge and Halliwell.13 Reactive nitrogen species (RNS) are nitrogen-centered species analogous to ROS. Evidence indicates that such species are formed in vivo; some, such as nitric oxide, contribute to various biological signaling responses. Others, however, are powerful oxidants and nitrating species capable of damaging biomolecules; antioxidant protection also limits the damage inicted by RNS. Several such antioxidant functions have been ascribed to HSA. ROS/RNS Scavenging. HSA in plasma, or bovine serum albumin in articial systems, provides protection from lipid peroxidation propagated by inorganic ROS generated from xanthine oxidase/hypoxanthine.14 However, thiol oxidation occurs, indicating the cys-34 moiety to be the source of the antioxidant protection afforded. In

more recent studies, hydrogen peroxide (H2O2) and the RNS peroxynitrite (ONOO) have been shown to oxidize cys-34 to a sulfenic acid derivative (HSA-SOH).15 This is subsequently converted to a disulde with the potential to be redox cycled to mercapto-albumin (HSASH), thereby restoring antioxidant function (Fig. 2). Increased ROS and RNS formation have been implicated as contributory factors in the onset and progression of critical illness.16 Albumin may provide effective extracellular scavenging antioxidant protection under such circumstances. Thus, albumin supplementation has been shown to replenish extracellular thiol status in patients with sepsis by means other than that which would be expected on purely stoichiometric grounds.17 Moreover, such supplementation was shown to improve thiol-dependent antioxidant protection in plasma obtained from patients with acute lung injury and to be associated with decreased levels of oxidative markers (protein carbonyls),18 although there was no difference in survival rates between groups. Persistent hypoalbuminemia is also associated with peroxidation of erythrocyte membranes in patients undergoing chronic hemodialysis, indicating that HSA protects against lipid oxidation.19 In vitro studies have shown that bovine serum albumin scavenges neutrophil-derived ROS, including hydrogen peroxide, superoxide, and hypochlorous acid.20 Inammatory cell-derived oxidants contribute to oxidative stress during acute inammation and the consequences thereof. HSA could potentially reduce such effects through scavenging antioxidant actions in humans, which may, also through modifying redox balance, regulate cell signaling moieties active in mediating pro-inammatory forces (Fig. 3). In vitro, albumin has been shown to offer antioxidant protection against the oxidative effects of carbon tetrachloride and uremic toxins,21,22 ndings with implications for both hepatic and renal failure. HSA may provide a supportive antioxidant role in vivo, through its ability to bind and transport substances with known antioxidant function, specically, bilirubin and NO, which are effective lipid phase antioxidants23,24 (Fig. 3). Bilirubin may also protect albumin from oxidant-mediated damage.25 Metal-Binding. Heme is thought to possess pro-oxidant properties through the redox properties of iron. HSA is an effective heme-binding protein.26 Once bound to albumin, such pro-oxidant properties are decreased, indicating an antioxidant function,27 although under physiological circumstances the heme-binding plasma protein hemopexin provides most of this form of antioxidant protection.28 Free, or loosely bound, redox-active transition metal ions (low molecular mass) are potentially extremely pro-oxidant, having the ability to catalyze the formation

1214

QUINLAN, MARTIN, AND EVANS

HEPATOLOGY, June 2005

of damaging and aggressive ROS from much more innocuous organic and inorganic species (Fig. 3). In strictly biological terms the 2 most important such metals are iron and copper. In specic circumstances (certain disease states and poisoning), these metal ions can become free of constraints, which normally limit and control their reactivity. By virtue of its high-afnity copper-binding site, HSA limits copper-catalyzed oxidative damage to other biomolecules by directing damage toward the albumin molecule itself in a sacricial fashion.29 In similar fashion, HSA can limit damage caused by accidental biological contamination by redox active metal ions such as vanadium, cobalt, and nickel. Although HSA iron-binding is weak and nonspecic, it may offer antioxidant protection when other specic protective stratagems become overwhelmed, such as under conditions of iron overload or pronounced hemolysis (Fig. 3). Anti-Inammatory Properties. Evidence indicates that accessible thiol groups can signal inammatory cell regulatory changes dependent on their redox state.30 Thus, 25% albumin has been shown to modulate neutrophil/endothelial cell interactions after shock and resuscitation and to attenuate lung injury.31 Furthermore, HSA augments intracellular glutathione levels and inuences activation of the ubiquitous transcription factor nuclear factor-kappa B using both in vitro and in vivo protocols.32 Moreover, several recent studies using a rat model of hemorrhagic shock have indicated that the type of resuscitation uid administered greatly inuences proinammatory responses, including lung apoptosis and rates of neutrophil activation. Plasma albumin was found to be the least proinammatory of the uids utilized.33 The formation of sulfenic acid residues by cys-34 oxidation15 also may be a key factor determining signaling responses, because recent evidence indicates that such groups impact on cellular signaling functions, reviewed in Poole et al.34 Pro-oxidant Implications. Paradoxically, and in common with other redox active antioxidant substances, albumin can display pro-oxidant properties, through its ability to redox cycle/recycle transition metal ions such as iron and copper from the less reactive (ferric/cupric) to more pro-oxidant (ferrous/cuprious) states (Fig. 3). Thus, a recent study has shown that copper/HSA could become pro-oxidant after fatty acid binding and subsequent cys-34 oxidation.35 Iron has much less binding afnity for HSA and is more likely to be recycled as a free agent able to catalyze damaging ROS formation at sites distant from HSA. Such an action is, therefore, potentially more deleterious. Indeed, HSA administration was reported recently to be adversely associated with a decline in ironbinding antioxidant protection in patients with acute lung injury,18 an effect thought to be related to the redox

cycling of iron. Intravenous albumin therefore may be inadvisable in circumstances when pronounced extracellular iron mobilization or overload are complicating factors. Synthesis and Turnover. In healthy adults, albumin synthesis occurs predominantly in polysomes of hepatocytes (10-15 g/day) and accounts for 10% of total liver protein synthesis. Relatively small amounts of albumin are hepatologically stored (2 g), the majority being released into the vascular space. Approximately 30%-40% of albumin synthesized is maintained within the plasma compartment. The remaining pool is located within tissues such as muscle and skin. Studies of radiolabeled albumin catabolism in normal healthy young adult males indicate a variation of half-life of between 12.7 and 18.2 days (mean, 14.8 days),36 although a dynamic exchange between plasma and the interstitium occurs. Albumin leaks from plasma at a rate of 5%/hour and is returned to the vascular space at an equivalent rate through the lymphatic system. Synthesis is a constant process, regulated at both transcriptional and posttranscriptional levels by specic stimuli, but change in interstitial colloid oncotic pressure is thought to be the predominant regulatory inuence.37 Albumin homeostasis is maintained by balanced catabolism that is not well characterized, occurring in all tissues. However, most albumin (40%-60%) is degraded in muscle, liver, and kidney. Plasma hyperalbuminemia is rare, whereas hypoalbuminemia is a feature of a variety of pathological processes, including liver disorders, cancer, and severe sepsis. Ascites formation is a common complication of cirrhosis and contributes to vascular hypoalbuminemia. Perturbations in hepatic vascular control are thought to be responsible for ascites formation, although the precise mechanisms remain a matter of debate (reviewed in Arroyo38). However, cirrhosis in the advanced stages is also characterized by protein wasting and hence albumin depletion. The reasons for such dysfunction remain unresolved, but nutritional, metabolic, and hormonal abnormalities and uncharacterized responses to the release of bioactive substances including chemokines may contribute to hyopalbuminemia (reviewed in Tessari39). The capillary bed is known to be hyperpermeable in patients with sepsis, thereby leaking albumin. However, the extent to which altered liver biosynthesis and rates of catabolism contribute to the plasma albumin deciency seen in sepsis and critical illness remains uncertain. Indeed, the half-life of HSA in patients with hypoalbuminemia supported with total parenteral nutrition is only 9 days, although rates of catabolism are normal.40 Moreover, catabolism actually may be decreased while the extracellular pool is increased, suggesting that HSA may be

HEPATOLOGY, Vol. 41, No. 6, 2005

QUINLAN, MARTIN, AND EVANS

1215

spared or protected.41 Studies in healthy individuals given endotoxin, as well as in the critically ill, indicate that albumin synthesis increases under these circumstances, even though hypoalbuminemia is common.42,43 By contrast, in animal models of sepsis and endotoxemia, decreased rates of liver albumin synthesis at the expense of acute phase protein synthesis is detectable regardless of nutritional support.44 Further studies in humans are required to resolve this controversy. Colloid Oncotic Pressure. HSA is a relatively small protein that accounts for some 75% of protein molecules in plasma in healthy individuals. Because of its disproportionate contribution to the plasma protein pool, albumin is also responsible for approximately 75% of plasma colloid oncotic pressure (COP). Oncotic pressure becomes osmotic pressure as the negative charges surrounding the protein molecules attract sodium, thus holding water. Its remaining contribution to COP is due to the Donnan effect attributable to its overall negative charge. Moreover, HSA may inuence directly vascular integrity by binding in the interstitial matrix and subendothelium and reducing the permeability of these layers to large molecules, and indirectly through its scavenging properties. Albumin as Therapy in Critical Illness. HSA has long been used to combat vascular collapse in severely ill patients, customarily as an iso-oncotic (4%-5%) solution for intravascular volume expansion; and as an hyperoncotic (20%-25%) solution for the maintenance of uid balance between compartments and the restoration of COP. More recently, the benets of HSA in supporting the critically ill have been debated, not least because it is expensive compared with synthetic colloid solutions. Concerns have been raised regarding the distribution of albumin in states of altered capillary permeability, such as sepsis. However, clinical trials have conrmed that albumin remains a potent volume expander compared with crystalloid solutions even under these circumstances.45 However, a recent study nding that bolus administration of 20% HSA to patients with sepsis led to a signicantly faster decline in plasma albumin compared with healthy controls raises questions about longer-term efcacy of albumin administration.46 Furthermore, in these states of altered capillary permeability, the formation of edema (such as pulmonary edema) is governed more by hydrostatic pressure than COP.47 Colloid administration to patients with acute lung injury does not worsen pulmonary edema and may in fact reduce edema-producing forces.48 A variety of meta-analyses have produced conicting results regarding the risk and benets of albumin administration to critically ill patients. Specically, the 1998 Cochrane Injuries Group concluded that albumin administration may increase the risk of death,49 whereas a

larger meta-analysis published subsequently found no difference in outcome.2 Systematic reviews have attempted to elucidate potential reasons as to why albumin would adversely affect outcome, but have failed to identify the mechanism.50 However, in one of the largest clinical trials ever conducted in critically ill patients, the SAFE study randomized 7,000 critically ill patients needing uid resuscitation to receive either 4% albumin or normal saline. There were no differences between groups in survival, measures of morbidity, and organ dysfunction, nor in length of stay in the intensive care unit or hospital.4 Is albumin neither benecial nor harmful in a therapeutic sense in the critically ill, despite its wide range of potentially signicant properties? We suggest that uncertainty remains for a number of reasons. First, the wide range of patients with critical illness that have been studied to date may conceal specic populations in which HSA may be denitely benecial or harmful. Indeed, HSA is increasingly recognized as a niche drug, evidenced by its ability to signicantly improve outcomes in patients with cirrhosis complicated by spontaneous bacterial peritonitis.51 This is further supported by subgroup analysis of the SAFE study,4 which has indicated that albumin may have varying effects in different patient groups. From these data, patients with traumatic brain injuries may actually be harmed by albumin administration (relative risk for death 1.62, P .009), whereas sepsis patients may derive benet (relative risk 0.87, P .06). Second, the use of albumin in all trials published to date has concentrated on its volume-expanding effects. The total dose administered may therefore be inappropriate if other, non-circulatory properties such as those relating to antioxidant or anti-inammatory capacities are the desired end point. Such properties might account for any disease-specic (i.e., niche) effects of HSA therapy. Third, albumin may have valuable properties when used as an adjunct with other therapies, as in hypoproteinemic patients with acute lung injury and acute respiratory distress syndrome, where the combination of HSA and furosemide therapy has been shown to improve uid balance, oxygenation, and hemodynamics.48 The mechanisms responsible for the benets observed in acute lung injury and acute respiratory distress syndrome are incompletely understood and may be specic to albumin compared with synthetic colloids. There is no clear evidence that pulmonary edema may be inuenced by one colloid more than another.47 The ability of HSA to bind many drugs, sometimes irreversibly, is a complicated issue that may impact on combinational therapies.52,53 Furthermore, binding of biologically active moieties such as NO (NO), levels of which become elevated during crit-

1216

QUINLAN, MARTIN, AND EVANS

HEPATOLOGY, June 2005

Table 1. Study Findings: Treatment of Cirrhosis by Albumin

Cirrhosis Treatment Albumin Comments

Ascites Independent risk for renal impairment

Paracentesis

Plasma volume expansion

Hepatorenal syndrome Common complication of advanced cirrhosis resulting in renal failure Spontaneous bacterial peritonitis Risk of renal impairment potentiated

Vasoconstrictor drugs Renal replacement therapy

Plasma volume expansion

Paracentesis alone results in pronounced renal impairment in a signicant proportion of patients. In combination with albumin volume expansion, this is almost completely prevented Albumin more effective than other volume expanders Long-term albumin treatment together with the administration of arterial vasoconstrictors reverses hepatorenal syndrome in most patients, use of vasoconstrictors alone is much less effective Renal impairment develops in a third of patients treated with antibiotics, but this was substantially decreased if albumin is given in combination with antibiotics at time of diagnosis, mortality was also lower

Non-nephrotoxic antibiotics

Combinational use

NOTE. Summarizes ndings of studies into the use of intravenous albumin for the treatment of cirrhosis. It is not an exhaustive list. More detailed reviews of current literature can be found in Arroyo38 and Grange and Amiot69 (used to compile this table).

ical illness, may inuence the ability of HSA to bind other ligands.54

Albumin as Therapy in Liver Disease

Historically albumin was used in patients with cirrhosis for vascular volume maintenance, because of its oncotic properties. As theories regarding the nature of vascular control and ascites formation developed, and with a better understanding of the use of diuretics and other management strategies, the use of albumin for the treatment of this condition declined. However, it is now apparent that the volume-expanding properties of albumin, in combination with other therapeutic approaches, is of clinical benet to patients with cirrhosis, thereby reducing the renal impairment that complicates liver disease38 (Table 1). Recently albumin has been used not as a medium for administration, but as a part of a hemodialysis regimen in patients with hepatic failure, the so-called molecular adsorbent recirculating system (MARS, for a review see Sen et al.55). MARS uses an albumin-containing dialysate that is regenerated by dialysis against buffered bicarbonate solution subsequent to carbon and anion exchange column treatment to combine the removal of toxins normally cleared by the kidneys with those removed by the liver. MARS has been used to treat liver dysfunction and failure in more than 4,000 patients over the last 4 years56 and has been shown to improve renal function and hemodynamics, and to decrease brain edema and hepatic encephalopathy (reviewed in Mitzner et al.57). HSA avidly binds toxins, including bilirubin, copper ions, and protein breakdown products, substances that accumulate in primary liver diseases including cirrhosis,58 hepatitis C infection,59 and Wilsons disease.60 There are also indications for the treatment of secondary liver disease and during

posttransplantation complications. The ability of MARS to remove other toxins and pro-inammatory stimuli such as lipopolysaccharides, chemokines, and lipid peroxidation end-products, xenobiotics and free heme/ hemoglobin, may have implications for limiting the inammatory response. Ample evidence exists of enhanced NO production during both chronic and acute liver failure61 that may relate to adverse clinical events such as renal impairment and circulatory dysfunction, including hepatopulmonary syndrome. NO is specically bound by HSA at position cys-34, MARS treatment may therefore also help modulate circulatory NO levels during liver failure, thereby protecting against the cascade of other organ failures that accompany acute liver disease. However, as previously stated, the levels of s-nitroso-albumin found in healthy plasma subjected to relevant physiological exposure with NO are low. Caution should therefore be used when interpreting results of MARS trials in this context, with the need for the true extent of s-nitrosylation to be determined under such pathological circumstances. There may well be implications for hepatopulmonary syndrome, although studies in this area are somewhat limited. However, the MARS system has been used to treat a small number of patients with ARDS.62 Contraindications. Recognized contraindications to albumin therapy include a known allergy to albumin and states in which uid overload could be harmful (decompensated congestive heart failure or hypertension, severe anemia, etc.). Administration of certain colloids may be contraindicated in specic patient populations, such as dextrans or starches in patients with clinically signicant coagulopathies, or hetastarch to patients with severe sepsis.63 Whereas albumin has similar colligative properties to these synthetic colloids, the adverse effect prole is less

HEPATOLOGY, Vol. 41, No. 6, 2005

QUINLAN, MARTIN, AND EVANS

1217

Table 2. Theoretical Pros and Cons Associated with Intravenous HSA Use
Theoretical Benets Potential Adverse Effects Comments

Intravascular maintenance and volume expansion

Fluid overload as plasma volume responds linearly to levels of HSA administered Allergic reactions Manufacturer and batch variation in albumin for clinical use.

Drug interactions

Drug interactions

Increased interstitial clearance Removal of endogenous toxins

Removal of exogenous toxins Maintenance of extracellular redox status Scavenging antioxidant protection Heme-binding antioxidant protection

Brain trauma N-terminal metal-binding and antioxidant protection Nonspecic iron-binding and antioxidant protection Also pro-oxidant implications

Nitric oxide-binding

Nitric oxide-binding

No enhanced outcome benet compared with other colloids, but less likely to see adverse drug reactions A rare occurrence may be associated with polymer formation on storage of HSA Variable levels of reduced thiols present, higher oxidation states seen. Bound reactive metal ions including copper, iron, vanadium, and aluminum seen The ability to bind an array of drugs may in some instances aid drug transport and delivery but equally some covalent interactions may be irreversible, thereby compromising drug efcacy. Binding of other ligands may also inuence drug interactions with HSA Enhanced albumin clearance when administered to patients with sepsis Liver dysfunction: HSA binds bilirubin, copper and nitric oxide as well as other liver-derived toxins. May also help remove pro-inammatory substances such as chemokines Metal poisoning, and certain drugs Plasma thiol repletion Cys-34mediated removal of hydrogen peroxide and other ROS High-afnity heme-binding may come into play when other (hemopexin) antioxidant protection is overwhelmed or decient. Adverse indications High-afnity binding of reactive transition metal ions; Copper, cobalt and nickel directs oxidative damage to albumin rather than other biomolecules May offer antioxidant protection when other (transferrin) iron-binding antioxidant protection is overwhelmed or decient. However, as HSA is redox active it can potentially recycle iron to the more catalytically active ferrous state NO bound to HSA may represent a proportion of an in vivo sink for this vasoactive gas, the actions of which may be either benecial or deleterious dependant on circumstances and organ type.

NOTE. Treatment of the critically ill are described. This is not an exhaustive list, but it summarizes areas highlighted and cited in this review.

cumbersome, although it could be pro-oxidant under dened circumstances with as yet unknown consequences. Finally, HSA from different manufacturers may differ markedly in terms of the types of metals bound to it and in levels of oxidation.64 Albumin employed for clinical use therefore may differ markedly from endogenous HSA. Such batch differences may inuence biochemical properties, and HSA can thereby vary in its ability to inuence adhesion molecule expression from endothelial cells in culture.65 Furthermore, dimer and polymer formation on storage may contribute to rare instances of allergic reactions being seen,66 and vanadium contamination of commercial batches of HSA has been shown to adversely inuence renal function in patients with coronary heart disease.67 Table 2 describes theoretical/potential implications associated with intravenous albumin administration. A more complete description of possible adverse

effects from colloid administration can be found in a recent review.68

Summary
Human serum albumin (HSA) has many physiological and biochemical properties that render it relevant to many aspects of the disordered vascular and cellular functions that characterize the critically ill; particularly those aficted by the systemic inammatory response syndromesepsis, severe sepsis, and septic shock. The use of albumin as a routine volume expanding agent in the intensive care setting cannot be justied in terms of a mortality or morbidity advantage over crystalloid solutions. However, albumin may be benecial in specic clinical circumstances, such as in patients with cirrhosis complicated by SBP, and its potential to modulate the inam-

1218

QUINLAN, MARTIN, AND EVANS

HEPATOLOGY, June 2005

matory response is, we suggest, worthy of further exploration. Acknowledgment: The authors thank the British Heart Foundation, The Dunhill Medical Trust, The Gareld Weston Trust and the David Boston Trust for their support, and the U.S. National Institutes of Health for support via grant HL-67739.

References
1. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, CA: Academic Press, 1996. 2. Wilkes MM, Navickis RJ. Patient survival after human albumin administration: a meta-analysis of randomized, controlled trials. Ann Intern Med 2001;135:149-164. 3. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for uid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247-2256. 4. Finfer S, Norton R, Bellomo R, Boyce N, French J, Myburgh J. The SAFE study: saline vs. albumin for uid resuscitation in the critically ill. Vox Sang 2004;87(Suppl 2):123-131. 5. Droge W. Aging-related changes in the thiol/disulde redox state: implications for the use of thiol antioxidants. Exp Gerontol 2002;37:13331345. 6. Kragh-Hansen U, Chuang VT, Otagiri M. Practical aspects of the ligandbinding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;25:695-704. 7. Janatova J, Fuller JK, Hunter MJ. The heterogeneity of bovine albumin with respect to sulfhydryl and dimer content. J Biol Chem 1968;243: 3612-3622. 8. Scharfstein JS, Keaney JF Jr, Slivka A, Welch GN, Vita JA, Stamler JS, et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 1994;94:1432-1439. 9. Wang X, Tanus-Santos JE, Reiter CD, Dejam A, Shiva S, Smith RD, et al. Biological activity of nitric oxide in the plasmatic compartment. Proc Natl Acad Sci U S A 2004;101:11477-11482. 10. Liu L, Yan Y, Zeng M, Zhang J, Hanes MA, Ahearn G, et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 2004; 116:617-628. 11. Masuoka J, Saltman P. Zinc(II) and copper(II) binding to serum albumin: a comparative study of dog, bovine, and human albumin. J Biol Chem 1994;269:25557-25561. 12. Loban A, Kime R, Powers H. Iron-binding antioxidant potential of plasma albumin. Clin Sci (Lond) 1997;93:445-451. 13. Gutteridge John MC, Halliwell B. Free Radicals in Biology and Medicine. 3rd ed. Oxford: Oxford University Press, 1998. 14. Radi R, Bush KM, Cosgrove TP, Freeman BA. Reaction of xanthine oxidase-derived oxidants with lipid and protein of human plasma. Arch Biochem Biophys 1991;286:117-125. 15. Carballal S, Radi R, Kirk MC, Barnes S, Freeman BA, Alvarez B. Sulfenic acid formation in human serum albumin by hydrogen peroxide and peroxynitrite. Biochemistry 2003;42:9906-9914. 16. Lang JD, McArdle PJ, OReilly PJ, Matalon S. Oxidant-antioxidant balance in acute lung injury. Chest 2002;122:314S-320S. 17. Quinlan GJ, Margarson MP, Mumby S, Evans TW, Gutteridge JM. Administration of albumin to patients with sepsis syndrome: a possible benecial role in plasma thiol repletion. Clin Sci (Lond) 1998;95:459-465. 18. Quinlan GJ, Mumby S, Martin GS, Bernard GR, Gutteridge JM, Evans TW. Albumin inuences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med 2004;32:755-759. 19. Soejima A, Matsuzawa N, Miyake N, Karube M, Fukuoka K, Nakabayashi K, et al. Hypoalbuminemia accelerates erythrocyte membrane lipid peroxidation in chronic hemodialysis patients. Clin Nephrol 1999;51:92-97.

20. Kouoh F, Gressier B, Luyckx M, Brunet C, Dine T, Cazin M, et al. Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco 1999;54:695-699. 21. Wratten ML, Sereni L, Tetta C. Oxidation of albumin is enhanced in the presence of uremic toxins. Ren Fail 2001;23:563-571. 22. Ogasawara Y, Isoda S, Tanabe S. Antioxidant effects of albumin-bound sulfur in lipid peroxidation of rat liver microsomes. Biol Pharm Bull 1999; 22:441-445. 23. Rubbo H, Parthasarathy S, Barnes S, Kirk M, Kalyanaraman B, Freeman BA. Nitric oxide inhibition of lipoxygenase-dependent liposome and lowdensity lipoprotein oxidation: termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Arch Biochem Biophys 1995;324:15-25. 24. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin-bound bilirubin. Proc Natl Acad Sci U S A 1987;84:5918-5922. 25. Neuzil J, Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBS Lett 1993;331:281-284. 26. Wardell M, Wang Z, Ho JX, Robert J, Ruker F, Ruble J, et al. The atomic structure of human methemalbumin at 1.9 A. Biochem Biophys Res Commun 2002;291:813-819. 27. Vincent SH, Grady RW, Shaklai N, Snider JM, Muller-Eberhard U. The inuence of heme-binding proteins in heme-catalyzed oxidations. Arch Biochem Biophys 1988;265:539-550. 28. Gutteridge JM, Smith A. Antioxidant protection by haemopexin of haemstimulated lipid peroxidation. Biochem J 1988;256:861-865. 29. Gutteridge JM, Wilkins S. Copper salt-dependent hydroxyl radical formation: damage to proteins acting as antioxidants. Biochim Biophys Acta 1983;759:38-41. 30. Haddad JJ. Oxygen homeostasis, thiol equilibrium and redox regulation of signalling transcription factors in the alveolar epithelium. Cell Signal 2002; 14:799-810. 31. Powers KA, Kapus A, Khadaroo RG, He R, Marshall JC, Lindsay TF, et al. Twenty-ve percent albumin prevents lung injury following shock/resuscitation. Crit Care Med 2003;31:2355-2363. 32. Cantin AM, Paquette B, Richter M, Larivee P. Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation. Am J Respir Crit Care Med 2000;162:1539-1546. 33. Alam HB, Stanton K, Koustova E, Burris D, Rich N, Rhee P. Effect of different resuscitation strategies on neutrophil activation in a swine model of hemorrhagic shock. Resuscitation 2004;60:91-99. 34. Poole LB, Karplus PA, Claiborne A. Protein sulfenic acids in redox signaling. Annu Rev Pharmacol Toxicol 2004;44:325-347. 35. Gryzunov YA, Arroyo A, Vigne JL, Zhao Q, Tyurin VA, Hubel CA, et al. Binding of fatty acids facilitates oxidation of cysteine-34 and converts copper-albumin complexes from antioxidants to prooxidants. Arch Biochem Biophys 2003;413:53-66. 36. Beeken WL, Volwiler W, Goldsworthy PD, Garby LE, Reynolds WE, Stogsdill R, et al. Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest 1962;41:1312-1333. 37. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000;85:599-610. 38. Arroyo V. Review article: albumin in the treatment of liver diseasesnew features of a classical treatment. Aliment Pharmacol Ther 2002;16(Suppl 5):1-5. 39. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myobrils. Curr Opin Clin Nutr Metab Care 2003;6:79-85. 40. Spiess A, Mikalunas V, Carlson S, Zimmer M, Craig RM. Albumin kinetics in hypoalbuminemic patients receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr 1996;20:424-428. 41. Rothschild MA, Oratz M, Schreiber SS. Extravascular albumin. N Engl J Med 1979;301:497-498. 42. Barle H, Januszkiewicz A, Hallstrom L, Essen P, McNurlan MA, Garlick PJ, et al. Albumin synthesis in humans increases immediately following the administration of endotoxin. Clin Sci (Lond) 2002;103:525-531. 43. Essen P, McNurlan MA, Gamrin L, Hunter K, Calder G, Garlick PJ, et al. Tissue protein synthesis rates in critically ill patients. Crit Care Med 1998; 26:92-100.

HEPATOLOGY, Vol. 41, No. 6, 2005

QUINLAN, MARTIN, AND EVANS

1219

44. OLeary MJ, Koll M, Ferguson CN, Coakley JH, Hinds CJ, Preedy VR, et al. Liver albumin synthesis in sepsis in the rat: inuence of parenteral nutrition, glutamine and growth hormone. Clin Sci (Lond) 2003;105: 691-698. 45. Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med 1999;27:46-50. 46. Margarson MP, Soni NC. Changes in serum albumin concentration and volume expanding effects following a bolus of albumin 20% in septic patients. Br J Anaesth 2004;92:821-826. 47. Lewis CA, Martin GS. Understanding and managing uid balance in patients with acute lung injury. Curr Opin Crit Care 2004;10:13-17. 48. Martin GS, Mangialardi RJ, Wheeler AP, Dupont WD, Morris JA, Bernard GR. Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. Crit Care Med 2002;30:2175-2182. 49. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers. BMJ 1998;317:235-240. 50. Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs. colloids in uid resuscitation: a systematic review. Crit Care Med 1999;27:200-210. 51. Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-409. 52. Bertucci C, Domenici E. Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr Med Chem 2002;9:1463-1481. 53. De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002;41:1135-1151. 54. Kashiba-Iwatsuki M, Miyamoto M, Inoue M. Effect of nitric oxide on the ligand-binding activity of albumin. Arch Biochem Biophys 1997;345:237242. 55. Sen S, Jalan R, Williams R. Liver failure: basis of benet of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 2003; 35:1306-1311. 56. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002;22(Suppl 2):20-25. 57. Mitzner S, Loock J, Peszynski P, Klammt S, Majcher-Peszynska J, Gramowski A, et al. Improvement in central nervous system functions

58.

59.

60.

61.

62.

63.

64.

65.

66. 67.

68. 69.

during treatment of liver failure with albumin dialysis MARS: a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002;17:463-475. Pares A, Cisneros L, Salmeron JM, Caballeria L, Mas A, Torras A, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004;99:1105-1110. Doria C, Mandala L, Smith J, Vitale CH, Lauro A, Gruttadauria S, et al. Effect of molecular adsorbent recirculating system in hepatitis C virusrelated intractable pruritus. Liver Transplant 2003;9:437-443. Sen S, Felldin M, Steiner C, Larsson B, Gillett GT, Olausson M, et al. Albumin dialysis and Molecular Adsorbents Recirculating System (MARS) for acute Wilsons disease. Liver Transpl 2002;8:962-967. Leifeld L, Fielenbach M, Dumoulin FL, Speidel N, Sauerbruch T, Spengler U. Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expression in fulminant hepatic failure. J Hepatol 2002; 37:613-619. Peek GJ, Killer HM, Sosnowski MA, Firmin RK. Modular extracorporeal life support for multiorgan failure patients. Liver 2002;22(Suppl 2):69-71. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-916. Quinlan GJ, Coudray C, Hubbard A, Gutteridge JM. Vanadium and copper in clinical solutions of albumin and their potential to damage protein structure. J Pharm Sci 1992;81:611-614. Nohe B, Dieterich HJ, Eichner M, Unertl K. Certain batches of albumin solutions inuence the expression of endothelial cell adhesion molecules. Intensive Care Med 1999;25:1381-1385. Doweiko JP, Nompleggi DJ. Use of albumin as a volume expander. JPEN J Parenter Enteral Nutr 1991;15:484-487. Heinemann G, Braun S, Overbeck M, Page M, Michel J, Vogt W. The effect of vanadium-contaminated commercially available albumin solutions on renal tubular function. Clin Nephrol 2000;53:473-478. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med 2004;170:1247-1259. Grange JD, Amiot X. Nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice. Eur J Gastroenterol Hepatol 2004;16:567-570.